The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of thrombosis is listed in the absolute pro ll peripheral self-expanding stent system instructions for use as a possible vessel use complication.A conclusive cause for the reported patient effect, and the relationship to the product, if any, cannot be determined.However, the treatments appear to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
Patient id: (b)(6).It was reported that the procedure was performed on (b)(6) 2021, treating a target lesion in the mildly calcified left superficial femoral artery.Pre-dilatation was performed and the 6.0 x 120 mm absolute pro ll stent was implanted.Post-dilatation was performed.On (b)(6) 2022, the patient was re-hospitalized with thrombosis in the implanted stent and necrosis of the toes on the left foot.On (b)(6) 2022, the patient underwent amputation of the 3rd, 4th and 5th toes, left foot.On (b)(6) 2022, thrombus aspiration and drug-coated balloon angioplasty was performed at the target lesion, as well as at the posterior tibial artery, iliac artery and popliteal artery, non-study vessels.On (b)(6) 2022, the patient underwent a second surgical procedure, with amputation of the 5th metatarsal of the left foot.The event resolved on (b)(6) 2022.No additional information was provided.
|